

## ERRATUM

### Evaluation of Hexadecyloxypropyl-9-*R*-[2-(Phosphonmethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections

George R. Painter, Merrick R. Almond, Lawrence C. Trost, Bernhard M. Lampert, Johan Neyts, Erik De Clercq, Brent E. Korba, Kathy A. Aldern, James R. Beadle, and Karl Y. Hostetler

*Chimerix Incorporated, 5007 Southpark Drive, Durham, North Carolina 27713; Rega Institute for Medical Research, Faculty of Medicine, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium; Division of Molecular Virology and Immunology, Georgetown University Medical Center, Rockville, Maryland 20850; and Veterans Medical Research Foundation and Department of Medicine, University of California, San Diego, La Jolla, California 92093-0676*

Volume 51, no. 10, p. 3505–3509, 2007. Page 3506, column 1, line 25: “HDP-(S)-HPMPA” should read “CMX157” both times in this line.